Every Form 4 that Sarepta Therapeutics,, Inc. (SRPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SRPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRPT filings page.
Sarepta Therapeutics, Inc. (SRPT) reported that its Chief Financial Officer, Ryan Ho-Yan Wong, had 13,272 shares of common stock withheld on September 4, 2026 to pay tax liabilities tied to the vesting of restricted stock units granted on September 3, 2025. After this withholding, he directly holds 121,792 shares of Sarepta common stock. No transactions were made under a Rule 10b5-1 trading plan.
Sarepta Therapeutics, Inc. (SRPT) reported that Chief Operating Officer Ian Michael Estepan had 24,799 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units granted on September 3, 2025. The shares were valued at $22.22 per share for this withholding transaction, and Estepan now directly holds 177,184 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Sarepta Therapeutics, Inc. (SRPT) reported that EVP, General Counsel Cristin Rothfuss had 22,025 shares of common stock withheld on September 4, 2026 to pay tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. After this tax-related disposition, Rothfuss directly holds 115,519 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported.
Sarepta Therapeutics, Inc. (SRPT) reported that Louise Rodino-Klapac, President, R&D and Tech Ops, had 21,423 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. This was a disposition of shares for tax payment rather than an open‑market sale, and no Rule 10b5-1 trading plan is reported. After this withholding, she directly held 203,900 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. reported that Chief Executive Officer Michael Severino received significant equity awards on 2026-07-28. He was granted 2,224,342 stock options with a $17.74 exercise price, expiring 2036-07-28; 25% vests on 2027-07-28 and the remainder vests monthly over four years. He also received 756,104 restricted stock units, each for one share of common stock, vesting in substantially equal annual installments over four years, bringing his reported direct holdings to 2,224,342 options and 756,104 shares.
Boor Kathryn Jean reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. director Kathryn Jean Boor received an equity grant in the form of restricted stock units. She was granted 16,875 RSUs, each representing one share of common stock, at no cash cost. The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's meeting. Following this grant, she directly holds 25,138 shares of common stock.
Mayo Stephen reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Stephen Mayo received an equity grant in the form of restricted stock units. He was awarded 16,875 RSUs of common stock at no purchase price. Each RSU represents one share of common stock.
The RSUs will vest on the earlier of the one-year anniversary of the grant date and the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Mayo directly holds 18,640 shares of Sarepta common stock.
Wigzell Hans Lennart Rudolf reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Hans Lennart Rudolf Wigzell reported a stock-based compensation grant. He was awarded 16,875 restricted stock units (RSUs), each representing one share of Sarepta common stock at no cash cost. The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this award, Wigzell directly holds 42,098 shares of Sarepta common stock. This represents a routine equity compensation grant rather than an open-market share purchase.
BEHRENS M KATHLEEN reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Kathleen M. Behrens reported a compensation-related equity grant rather than an open-market trade. She was awarded 16,875 restricted stock units (RSUs), each representing the right to receive one share of common stock at no cost. According to the terms, these RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting. Following this grant, she holds 214,357 shares of common stock directly, and a separate filing entry shows 10,000 shares of common stock held indirectly by a trust as a reported holding.
Sarepta Therapeutics, Inc. reported that director Deirdre P. Connelly acquired 16,875 shares of common stock through a grant of restricted stock units (RSUs) at $0.00 per share as director compensation. Following this award, she directly holds 22,100 shares of Sarepta common stock.
The footnote explains that each RSU represents one share of common stock and will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. This is a stock-based compensation grant rather than an open-market purchase.
Nicaise Claude reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Claude Nicaise received a grant of 16,875 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost per share and increase his directly held position to 48,407 shares of common stock.
Each RSU represents the right to receive one share of Sarepta common stock. The RSUs will vest on the earlier of one year from the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting, aligning vesting with the company’s annual meeting cycle.
Chambers Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Michael Andrew Chambers reported an equity award of 16,875 shares of common stock in the form of restricted stock units. The RSUs were granted at no cash cost per share and will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it occurs at least 50 weeks after the prior annual meeting. Following this grant, Chambers holds 27,535 shares directly, in addition to 476,492 shares held indirectly through a revocable trust.
Barry Richard reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. reported that director Barry Richard received a grant of 16,875 shares of Common Stock as restricted stock units (RSUs) at a price of $0.00 per share. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's annual meeting.
Following this grant, Richard directly holds 2,983,542 shares of Sarepta common stock. He also has indirect ownership of 10,000 shares through an LLC and 240,000 shares through a trust, as reported in the filing.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported a routine tax-related share disposition. On March 11, he had 1,097 shares of common stock withheld by the company at $17.03 per share to cover tax obligations tied to vesting of restricted stock units granted on March 10, 2025. After this withholding, he directly held 201,983 shares of Sarepta common stock, indicating he retains a substantial equity position in the company.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a small share disposition tied to tax withholding, not an open-market trade. On March 11, 256 shares of common stock were withheld by the company at $17.03 per share to cover taxes on restricted stock units that vested from a grant dated March 10, 2025.
After this tax-withholding event, Wong directly holds 135,064 shares of Sarepta common stock. Because the shares were withheld to satisfy tax obligations rather than sold in the market, this filing reflects a routine compensation-related adjustment rather than a discretionary purchase or sale.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, had 948 shares of common stock withheld on March 11, 2026 to cover tax obligations linked to restricted stock units that vested from a grant dated March 10, 2025. The shares were valued at $17.03 each for this tax-withholding calculation. After this transaction, she directly holds 225,323 shares of common stock, indicating this was a small, routine adjustment related to equity compensation rather than an open-market trade.
Sarepta Therapeutics director Stephen Mayo reported an open-market sale of 7,239 shares of common stock at $17.02 per share. According to the footnote, this sale was made to generate cash to pay taxes arising from the vesting of restricted stock unit awards, indicating a tax-driven transaction rather than a discretionary portfolio move. After the sale, Mayo directly held 1,765 Sarepta shares.
Sarepta Therapeutics, Inc. executive Cristin Rothfuss, EVP and General Counsel, reported a routine tax-related share disposition. On March 11, 2026, the company withheld 974 shares of common stock at $17.03 per share to satisfy tax obligations from restricted stock units that vested on March 10, 2025.
After this withholding, Rothfuss directly holds 137,544 shares of Sarepta common stock, so the transaction represents only a small portion of her overall position and does not reflect an open-market sale.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported routine share dispositions tied to tax withholding on restricted stock unit vesting. On March 9, 2026, a total of 275 shares of common stock were withheld by the company to cover tax obligations from RSUs granted in 2022 and 2023. Following these tax-withholding events, Wong directly holds 135,320 shares of Sarepta common stock, so the withheld amount represents a modest adjustment to his overall equity position rather than an open-market sale.
Sarepta Therapeutics, Inc. executive vice president and general counsel Cristin Rothfuss reported routine share dispositions related to tax withholding. The company withheld a total of 830 shares of common stock at $16.95 per share to cover tax obligations on restricted stock units that vested from grants dated March 7, 2022 and March 6, 2023. Following these tax-withholding entries, Rothfuss directly holds 138,518 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, reported routine tax-related share dispositions. On March 9, 2026, a total of 1,399 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations on vesting restricted stock units granted in 2022 and 2023. After these withholdings, she directly holds 226,271 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported routine share dispositions tied to tax withholding rather than open-market sales. On March 9, 2026, a total of 1,619 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations from vesting restricted stock units granted on March 7, 2022 and March 6, 2023. After these transactions, Estepan directly owned 203,080 shares of Sarepta common stock.
Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a tax-related share disposition linked to restricted stock vesting. On March 2, 2026, 450 shares of common stock were withheld by the company at $16.20 per share to cover tax withholding obligations from restricted stock units granted on March 1, 2024. After this withholding transaction, Wong directly owned 135,595 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported equity award activity tied to prior grants. On March 1, 2026, 8,125 Performance Stock Units earned under a March 1, 2024 award were converted into 8,125 shares of common stock as they vested based on milestone achievement.
To cover tax withholding on the vesting of this PSU award and related restricted stock units, the company withheld a total of 4,176 shares of common stock on March 2, 2026, valued at $16.20 per share, as tax-withholding dispositions. After these non‑market transactions, Estepan directly owned 204,699 common shares.
Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity. On March 1, 2026, 8,125 Performance Stock Units previously earned under a March 1, 2024 PSU award vested and were converted into the same number of common shares, based on the compensation committee’s milestone achievement determination. On March 2, 2026, the company withheld 3,718 and 767 common shares, respectively, at $16.20 per share to cover tax withholding obligations related to the vesting of PSU and RSU awards, leaving Rodino-Klapac with 227,670 directly held common shares.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares. On February 26, 2026, he exercised options for 2,069 shares and 5,381 shares of common stock at an exercise price of $13.71 per share. These transactions increased his directly held common stock to 200,750 shares, according to the filing footnote, and involved no reported open-market sales.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported an equity compensation transaction involving performance stock units. He acquired 1,875 performance stock units on February 25, 2026 as a grant/award, bringing his directly held performance stock units to 8,125.
According to the disclosure, these 1,875 shares represent units earned under a performance stock unit award originally granted on March 1, 2024, based on the compensation committee’s determination of the company’s achievement of specified milestones. The earned units are scheduled to vest on March 1, 2026, if he continues to provide service to the company through that date.
Sarepta Therapeutics, Inc. reported that executive Louise Rodino-Klapac, President of R&D and Tech Ops, acquired 1,875 Performance Stock Units (PSUs) on the basis of a prior equity award. These PSUs were earned under a PSU grant originally awarded on March 1, 2024.
The number of PSUs earned reflects the compensation committee’s assessment of the company’s achievement of specified milestones in that award. Following this transaction, Rodino-Klapac holds a total of 8,125 PSUs. The earned PSUs are scheduled to vest on March 1, 2026, provided she continues to serve the company through that date.
Sarepta Therapeutics director Claude Nicaise exercised stock options and adjusted his shareholdings. On January 29, 2026, he exercised 10,500 stock options at $13.71 per share, receiving 10,500 shares of common stock.
On the same date, 6,780 common shares were withheld by Sarepta, noted as satisfying payment of the option exercise price. After these transactions, Nicaise directly owned 31,532 shares of Sarepta common stock.
Sarepta Therapeutics director M. Kathleen Behrens reported an option exercise and related share withholding. On January 27, 2026, she exercised a stock option for 10,500 shares of common stock at $13.71 per share, converting a derivative award into owned stock.
To cover the option exercise cost, 6,494 shares of common stock were withheld by Sarepta at a price of $22.17 per share, as explained in the footnote. After these transactions, she held 197,482 shares of common stock directly and 10,000 shares indirectly through a trust.
Sarepta Therapeutics, Inc. (SRPT) reported an insider equity transaction by its President, R&D and Tech Ops, filed on a Form 4. On 11/17/2025, the officer had 4,582 shares of common stock withheld by the company at a price of $18.42 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding transaction, the officer directly beneficially owned 224,030 shares of Sarepta common stock.